Johnson & Johnson (NYSE:JNJ) Stock Holdings Raised by Culbertson A N & Co. Inc.

Culbertson A N & Co. Inc. raised its position in Johnson & Johnson (NYSE:JNJ) by 3.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,312 shares of the company’s stock after acquiring an additional 2,363 shares during the quarter. Johnson & Johnson accounts for about 1.9% of Culbertson A N & Co. Inc.’s investment portfolio, making the stock its 10th largest holding. Culbertson A N & Co. Inc.’s holdings in Johnson & Johnson were worth $12,043,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the company. Butensky & Cohen Financial Security Inc. increased its position in shares of Johnson & Johnson by 3.7% in the 1st quarter. Butensky & Cohen Financial Security Inc. now owns 24,220 shares of the company’s stock worth $3,831,000 after purchasing an additional 864 shares during the last quarter. Chickasaw Capital Management LLC grew its position in shares of Johnson & Johnson by 1.8% in the 1st quarter. Chickasaw Capital Management LLC now owns 18,237 shares of the company’s stock worth $2,885,000 after acquiring an additional 314 shares in the last quarter. Beese Fulmer Investment Management Inc. raised its position in shares of Johnson & Johnson by 2.9% during the 1st quarter. Beese Fulmer Investment Management Inc. now owns 121,402 shares of the company’s stock valued at $19,205,000 after acquiring an additional 3,459 shares in the last quarter. Benchmark Wealth Management LLC boosted its holdings in Johnson & Johnson by 74.2% in the first quarter. Benchmark Wealth Management LLC now owns 2,716 shares of the company’s stock worth $430,000 after purchasing an additional 1,157 shares during the period. Finally, Atlas Brown Inc. boosted its stake in Johnson & Johnson by 7.6% in the first quarter. Atlas Brown Inc. now owns 34,599 shares of the company’s stock valued at $5,473,000 after acquiring an additional 2,448 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on JNJ. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. TD Securities dropped their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, TD Cowen decreased their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $175.93.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Up 0.1 %

Shares of NYSE:JNJ opened at $164.28 on Thursday. The stock has a market capitalization of $395.37 billion, a price-to-earnings ratio of 10.24, a PEG ratio of 2.65 and a beta of 0.52. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a 50 day moving average price of $162.81 and a 200 day moving average price of $154.59. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the previous year, the firm posted $2.66 EPS. The company’s quarterly revenue was up 5.2% on a year-over-year basis. On average, research analysts anticipate that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.